Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PAION Deutschland was the German operating subsidiary of PAION focused on hospital-based sedation, anesthesia, and critical care pharmaceuticals. Its portfolio centered on remimazolam, marketed as Byfavo, and also included licensed hospital products such as GIAPREZA and XERAVA for European markets. Following insolvency proceedings opened on January 1, 2024, the operating business of PAION Deutschland GmbH and PAION AG was transferred in a company sale and has been continued since February 2024 by PAION Pharma GmbH under the Humanwell Healthcare Group. As a result, PAION Deutschland GmbH i.L. is no longer an active operating company and is being wound up.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PAION Deutschland.